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Influence of aldosterone on sodium, water and potassium
metabolism in chronic renal disease. To evaluate the physiological
importance of aldosterone in chronic renal disease, ii studies
were performed in nine patients with renal impairment of varying
etiology and severity during periods of normal and low sodium
intake. Decreased sodium excretion during sodium restriction
was accompanied by increased aldosterone excretion and this
anti-natriuretic effect could be reversed by the administration of
spironolactone. Constancy of urinary potassium excretion occur-
red during the period of sodium restriction and may have been
related to a combination of diminished distal sodium delivery
and increased aldosterone activity. Sodium restriction was also
associated with a diminution in renal concentrating capacity and
an improvement in renal diluting capacity. Only the improvement
in renal diluting capacity, as judged by the minimal urinary
osmolality achieved during an acute water load, could be
reversed by the administration of spironolactone. These results
thus suggest that aldosterone is of physiological importance to
the control of urinary sodium, potassium and water excretion in
patients with chronic renal disease.
Influence de l'aldosterone sur le metabolisme du sodium, de
l'eau et du potassium dans l'insuffisance renale chronique. Pour
juger de l'importance physiologique de l'aldostérone dans I'm-
suffisance rénale chronique, onze experiences ont été chez
pendant des périodes de régime normal ou pauvre en sodium, sur
neuf malades atteints d'insuffisance d'étiologies et de gravité
variable. Pendant les périodes de restriction sodée, Ia diminution
de l'excrétion du sodium était associée avec une excretion accrue
d'aldostérone. Cet effet antinatriuretique pouvait Ctre annulé par
l'administration de spironolactone. En periode de restriction
sodée, l'excrétion du potassium demeura constante, peut-être
sous l'influence combinée d'un apport sodé moindre au niveau
du tube distal et d'une activité plus grande de l'aldostérone. La
restriction sodée s'accompagnait egalement d'une capacité
moindre du rein a concentrer l'urine et d'une meilleure capacité
de dilution. Seule l'amélioration de Ia capacité rénale de dilution,
jugée par l'osmolalité urinaire minimale atteinte aprés surcharge
hydrique, pouvait ëtre annulée par l'administration de spirono-
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lactone. Ces résultats suggérent donc que l'aldostérone joue
un role physiologique important dans Ic contrOle de l'élimination
urinaire du sodium, du potassium et de l'eau chez les malades
atteints d'insuffisance renale chronique.
The control of sodium excretion in the presence of
normal renal function has been clearly demonstrated
to be dependent on factors other than glomerular
filtration rate and aldosterone activity [1—4]. Recent
studies have demonstrated that a "third factor" may
be involved in the regulation of sodium excretion in
experimental uremia [51 and in patients with chronic
renal failure [6, 7]. Moreover, the physiological role of
such a "third factor" may be more important in
chronic renal disease since, in contrast to normal sub-
jects, it is possible that aldosterone may not be in-
volved in the adjustments in sodium excretion in
patients with chronic renal disease. This possibility is
not unlikely since patients with advanced chronic renal
disease who are receiving a normal sodium intake
have been reported to have increased aldosterone
secretory rates [8, 9] and thus may have persistently
high endogenous levels of aldosterone. In the presence
of already increased aldosterone activity, sodium
restriction may not be associated with any significant
alternation in either the level of aldosterone activity
or the renal response to aldosterone. Some evidence
for such a circumstance has been provided by the
studies of Slatopoisky et al [6] in which the renal
response to alterations in sodium intake in patients
with severe chronic renal disease was found to be
unaltered by the prior administration of supraphysio-
logical levels of exogenous mineralocorticoid [6].
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Although these results clearly implicate factors other
than aldosterone in the regulation of sodium excretion
by patients with chronic renal disease [6], they do not
exclude an additional contributory role of aldosterone.
The present investigation was therefore undertaken
to examine whether aldosterone is involved in the
renal response to alterations in dietary sodium intake
in patients with chronic renal failure. The results
suggest that alterations in aldosterone activity do
indeed contribute to the renal response to sodium
restriction in patients with chronic renal disease, not
only with respect to sodium excretion, but also with
regards to the renal excretion of potassium and water.
Methods
Eleven studies were performed in nine patients with
chronic renal disease. None of the patients had clinical
evidence of uremia, edema, congestive heart failure,
urinary tract obstruction or urinary tract infection.
Each study consisted of a period on a normal sodium
intake (2 mEq/kg/day) followed by a period on a low
sodium intake (10 to 21 mEq/day). Each patient
received the same basic diet and fluid intake (3Oml/kg)
during periods of normal and low sodium intake. The
patients ingested all of the food and fluid offered them
throughout the study. A solution of sodium chloride
was added to the basic diet during periods of normal
sodium intake and was omitted during periods of low
sodium intake. The dietary protein intake averaged
0.75 g/kg/day and the caloric intake ranged from
30 to 45 calories/kg/day, depending on the amount
necessary to maintain a constant body weight in
each individual patient during the period of normal
sodium intake. The periods of normal sodium intake
ranged from 7 to 15 days and the periods of low
sodium intake ranged from 8 to 25 days. Sodium
restriction was instituted when a constant body weight
had been noted for at least three consecutive days, and
terminated when the urinary sodium concentration had
diminished to a low level that was constant for at least
three days or when the serum sodium concentration
approached 120 mEq/liter. Adverse clinical sympto-
matology was not observed during any of the studies.
Aldosterone excretion rates. After at least seven days
on a normal sodium intake, three consecutive 24 hour
urine collections were obtained for determination of
aldosterone excretion rates. Three additional 24 hour
urine collections were obtained consecutively at the
end of each period of sodium restriction for the same
determination. The acid-released conjugate of aldo-
sterone was measured using the double isotope method
of Kliman and Petersen [10]. The determinations were
done by the Biomedical Assay Laboratory, Worches-
ter, Mass., without knowledge of the sodium intake
of the patients.
Glomerular filtration rate and volume studies. Endo-
genous creatinine clearance (Cer) was used as an
index of glomerular filtration rate (GFR) in those
patients whose Ccr was greater than 10 mI/mm. The
mean of the and urea clearance was used as an
index of GFR when the Cc, was less than lOml/min.
Radioactive '311-tagged albumin, 35S-sulfate and tn-
tiated water were used to measure plasma volume,
extracellular fluid (ECF) volume and total body water,
respectively, during periods of normal and low sodium
intake.
Sodium and potassium balances. Sodium and potas-
sium balances were undertaken during ten of eleven
studies with analyses of both urine and stool. Twelve
hour urine volumes were collected from 7:30 AM to
7:30 PM and from 7:30 PM to 7:30 AM. Stool collec-
tions were divided into three day periods. A nitric-
perchloric acid homogenate of stools was analyzed
for sodium and potassium content. Blood specimens
were obtained every other day. The blood and urine
specimens were analyzed for sodium, chloride, potas-
sium, urea, creatinine and osmolality. Sodium, potas-
sium, urea, and creatinine were measured on the
Technicon Autoanalyzer, and chloride was measured
using an automatic Cotlove titrator. Urine and plasma
osmolalities were measured cryoscopically on an Ad-
vanced osmometer. Osmolar clearance (Csm) was
calculated by the formula: C0 = urine osmolality
(Uosm)/plasma osmolality (P0sm) x urine flow (V). Free
water clearance (CH20) and free water reabsorption
(TcH2O) were calculated respectively as CH20=
V —C0 and TCH2O =Cøsm —V. Clearances of creati-
nine and urea were calculated by standard methods.
Dilution and concentration tests. Standard dilution
and concentration tests were performed at the end of
both the normal and low sodium intake periods in the
following manner: on the morning of the dilution
tests, the patients emptied their bladders and then
ingested an oral water load (20 ml/kg) over the next
30 minutes. Four one-hour urine collections were then
obtained sequentially and blood specimens were
drawn at the midpoint of each urine collection period.
Hourly urine volumes were replaced with the oral
administration of an equivalent volume of water.
Following completion of the dilution test, fluid was
restricted for the remainder of the day so that the total
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24 hour intake did not exceed 30 mI/kg. At 9:00 PM
on the same evening, fluid was completely withdrawn
and five units of pitressin tannate in oil, shaken to a
fine emulsion, were injected intramuscularly. At
7:30 AM the patients emptied their bladders, three or
four one-hour urine collections were obtained con-
secutively, and blood specimens were drawn at the
midpoint of each urine collection period. The patients
were then placed on a low sodium intake until the
minimal urinary sodium concentration was achieved;
the urinary dilution and concentration tests were then
repeated at that time.
In two studies the period of normal sodium intake
was continued after completion of the concentration
tests, and the patients were treated with 9-c-fluoro-
hydrocortisone (1.0mg) orally every six hours for
five days. In a third study desoxycorticosterone acetate
(10 mg) was administered intramuscularly for five
days. On the fourth and fifth day of mineralocorticoid
administration, the dilution and concentration tests
were repeated in the same manner as described above.
Dietary sodium restriction was then instituted and
the concentration and dilution tests were repeated
when the minimal urinary sodium concentration was
achieved. Spironolactone (75 mg) was then admini-
stered orally every six hours for eight days and the
dilution and concentration tests were repeated on the
seventh and eighth day of its administration. In these
same three patients, formation of TCH2O was examined
after the performance of the concentration tests on
both normal and low sodium intakes. These studies
were performed during the infusion of l0% mannitol
in sodium chloride (45 mEq/liter) at 10 mI/mm for
11/2 to 2 hours. Aqueous vasopressin was also ad-
ministered (50 mU/kg/hr).
Results
Effect of prolonged sodium restriction on urinary
aldosterone excretion in chronic renal disease (Fig. 1).
Three consecutive measurements of daily aldosterone
excretion were obtained in nine patients after receiving
a normal sodium intake for at least one week; similar
measurements were then obtained in the same patient
on a low sodium intake after a minimal urinary
sodium concentration had been achieved (range:
8 to 25 days). The mean values for the three urinary
aldosterone excretion rates in each patient on a normal
and low sodium diet are shown in Fig. I. The mean
value observed on a normal sodium diet was 5.9±
SEM I 1g/24 h, and it increased after the period of
prolonged sodium deprivation to 28.9 SEM 8.4 tg/
24 hr. Although some values were within the range of
normal after prolonged sodium deprivation, all of
these values were increased when compared with the
observed excretion rate in the same patient during the
period of normal sodium intake. Arterial blood
pressure was not significantly different during periods
of normal and low sodium intake in any patient.
Effect of prolonged sodium restriction on glomerular
filtration rate, blood urea nitrogen, body weight, total
body water, extracellular fluid and plasma volume
(Tables 1 and2). In ten of the eleven studies in nine
patients, prolonged dietary sodium restriction was
associated with a diminution in GFR. The mean GFR
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Fig. 1. Effect of prolonged sodium restriction on a/dos/crone ex-
cretion rate. Aldosterone excretion rates were not increased in
any of the studies during the normal sodium intake but increased
in each patient during sodium restriction.
Sodium intake
Normal Low
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Table 1. Summary of patients with chronic renal disease on normal and low sodium intake
GFRb BUN
mi/mm mg/JOO ml
Patient Age/Sex Diagnosis a
normal low normal low
sodium sodium sodium sodium
W. M. 37/M Chronic glomerulonephritis 47.8 41.8 30 28
J. C. (1) 30/M Polycystic disease 50.6 40.3 24 19
J. C. (2) 72.0 54.0 C 16 17
L. H. 65/M Unilateral kidney 67.3 55.3 14 17
N. D. 35/F Chronic pyelonephritis 4.3 4.1 78 68
T. M. 2l/M Chronic glomerulonephritis 8.2 7.1 66 82
W. B. 31/M Lupus nephritis 11.0 6.1 80 131
J. J. 30/M Interstitial nephritis 12.0 5.4 73 94
J. P. (1) 24/F Chronic glomerulonephritis 5.5 5.0 47 54
J. P. (2) 4.2 3.5 64 62
P. N. 20/M Interstitial nephritis 21.0 24.0 38 39
Mean 28 22 48 56
P <0.05 <0.5
Diagnosis confirmed by histological examination of tissue obtained either by renal biopsy or at surgery.
h Endogenous creatinine clearance used as an estimate of glomerular filtration rate unless clearance less than 10 mI/mm when the
urea clearance -f- (real/rune clearance/2 was used.
There was no apparent explanation for the improved renal function during the second study.
Table 2. Effect of sodium restriction on body weight, total body water, extracellular fluid volume
and plasma volume
Weight Total body water ECF volume Plasma volume
kg liters liters ml
Patient — —_______________
normal low normal low normal low normal low
sodium sodium sodium sodium sodium sodium sodium sodium
W. M. 83.0 82.0 38.3 37.5 11.2 10.9 2841 2962
J.C. 83.7 80.5 40.2 38.8 11.0 11.0 3248 2946
L. H. 80.0 78.5 35.8 34.0 12.2 11.5 4013 3542
N. D. 37.0 37.4 19.2 18.6 7.2 7.0 2414 2275
T. M. 65.7 63.7 41.1 39.6 14.0 12.0 4356 3491
W. B. 56.7 54.5 30.0 28.0 9.6 9.0 3448 3125
J.J. 60.9 60.2 39.1 37.6 11.5 11.3 3350 3295
Mean 66.7 65.3 34.8 33.4 11.0 10.4 3381 3091
SEM 1.0 163
P <0.02 <0.001 <0.10 <.01
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in these patients decreased significantly' from 28 to
22 mI/mm. The increase in mean blood urea nitrogen
from 48 to 56 mg/lOO ml during the period of sodium
restriction was not significant. Sodium restriction was
associated with a significant reduction in mean body
weight from 66.7 to 65.3 kg. Volume measurements in
seven of the nine patients revealed a significant, though
modest, diminution in total body water in all, and a
reduction of extracellular fluid and plasma volume
in six of the seven patients. None of the patients
developed symptoms of hypovolemia during periods
of sodium restriction and a constant fluid intake.
Effect of prolonged sodium restriction on sodium and
potassium metabolism (Table 3, Fig. 2). The mean
daily sodium intake prior to sodium restriction was
138 mEq and the mean duration of these control
periods was eleven days (range: 7 to 15 days). The
mean daily sodium intake during the period of sodium
restriction was 11 mEq and the mean duration of
sodium restriction was 18 days (range: 8 to 25 days).
In eight of the nine patients, sodium restriction was
discontinued when the minimal urinary sodium con-
centration was achieved. In these eight patients,
Paired student "t" test: a P value <0.05 was considered to be
statistically significant.
although the achievement of a minimal urinary sodium
concentration was delayed from 8 to 25 days, sodium
balance was eventually achieved in each patient. In
the ninth patient (J. P.), the urinary sodium concen-
tration remained high and severe hyponatremia
developed rapidly. For this reason, dietary sodium
restriction was discontinued after nine days in this
patient (Fig. 2). Fecal losses of sodium were generally
insignificant during periods of both normal and low
sodium intake. The mean daily negative sodium
balance for the nine patients was 21 mEq, and an
average negative cumulative sodium balance of
—378 mEq was noted during the period of sodium
restriction (mean duration: 18 days). Sodium restric-
tion was associated with a slight but significant dimi-
nution in mean plasma sodium concentration from
141 to 136 mEq/liter, including the marked hypona-
tremia in J.P. (138 to 123 mEq/liter). Diurnal varia-
tions in urinary sodium excretion were not observed
in any of the nine patients and the 24 hour urine
volume was similar during periods of normal and low
salt intake. Spironolactone was administered to three
patients as the low sodium intake was continued
(Table 4). Aldosterone inhibition by spironolactone
was associated with an increase in urinary sodium
concentration and a decrease in urinary potassium
Table 3. Effect of sodium intake
Na intake Duration V Minimal UNaVa Fecal Na
UNUV losses
mEq/day Days mi/day on low mEq/day mEq/day
Patient sodium
Normal low normal low normal low intake normal low normal low
Na Na Na Na Na Na mEq/day Na Na Na Na
W. M. 169 21 8 11 2479 2506 5 134 26 1.5 3.2
L.H. 162 12 11 23 2146 2419 4 146 23 — 0.7
N.D. 75 10 12 25 1071 1294 15 48 22 — 0.2
T.M. 146 10 12 24 1528 1548 7 102 25 1.2 0.8
J.P. 88 9 7 8 1164 1122 34 67 44 11.0 2.4
J.C. 173 11 11 15 2368 2717 15 162 50 8.6 2.0
P. N. 190 12 10 19 2763 3083 6 161 45 5.3 0.5
J.J. 123 8 13 20 1798 1494 10 121 28 0.3 0.7
W. B. 113 10 15 21 1480 1293 10 113 20 0.7 1.3
Mean 138 11 11 18 1866 1942 12 117 31 4.0 1.3
±saM ±13 ±1 ±1 ±2 ±201 ±245 ±3 ±13 ±4 ±16 ±0.3
P <0.1 <0.001 <0.1
a Mean values for entire duration of normal and low sodium periods.
b Fecal sodium and potassium losses were not measured and are therefore not accounted for in the balance figures.
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concentration in all three patients. Free-water clear-
ance was decreased in two of the three patients. In
the same three patients mineralcorticoid administra-
tion (9-c-fluorohydrocortisone in J. C. and P. N.;
desoxycorticosterone acetate in J.J.) during a normal
sodium intake was associated with a decrease in urinary
Fig. 2. Effects of prolonged sodium restric-
tion on plasma sodium concentration, urine
flow, Cosm and CH2O. The patient on the
left (TM.) demonstrated the ability du-
ring sodium restriction to diminish C05m
and increase CH2O as V and 'DNa remain-
ed unchanged. The patient on the right
(J.P.) with "salt-losing nephritis" was
unable to diminish Csm and increase
CH2O during sodium restriction and thus
rapidly developed hyponatremia.
sodium concentration and an increase in urinary
potassium concentration and free-water clearance.
During the period of sodium restriction a modest
decrease in GFR occurred in all three patients during
the administration of spironolactone. Mineralocorti-
coid administration during a normal sodium intake
CH2O
(mI/mm) +1
U
0 5 10 15 20 25 30
Days
-J-l----35 0 5 10' 15 20
Days
on sodium and potassium balances
Mean daily Na K intake UKV Fecal Mean daily K
Na balance K losses K balance
,nEq/day mEq/liter mEq/day mEq/day mEq/day mEq/day mEq/liter
normal low normal low normal low normal low normal low normal low
Na Na Na Na Na Na Na Na Na Na Na Na
+33.5 — 8.2 144 139 81 66 65 13 27 — 2 —11 5.1 4.5
+16.Oh —11.7 133 134 96 92 87 — 5 + 4b + 4 4.5 5.8
+27.Ob —12.2 146 l38 57 34 38 — 6 +23b +15 5.4 55
+ 32.8 —15.8 142 139 47 37 47 7.0 5.5 + 3 — 5.5 4.5 3.6
+ 10.0 —37.4 138 123 60 9 15 30 29 +21 +16 6.4 6.1
+ 4.4 —41.0 142 138 84 68 57 21.5 15 — 5.5 +12 3.9 4.1
+33.7 —33.5 144 142 81 50 62 14 10 +17 + 9 4.7 4.7
+ 1.7 —20.7 145 143 33 26 30 7 7 0 — 4 4.4 5.1
— 0.7
—11.3 138 132 29 28 24 8 8 — 7 — 3 4.6 3.9
17.6 —21.3 141 136 63 46 47 14.4 12.5 6 4 4.8 4.8
+ 5 + 4 +1 +2 +8 +9 +8 +3 +3 + 4 + 3 +0.2 +0.3
<0.001 <0.05 <0.1 <0.1 c <0.1 <0.1
c "s" test performed only on studies with both normal and low sodium values.
Normal salt Low salt intakeTM-Chronic
glomerulonephritis
140Plasma sodium
concentration 130
(mEq/liter)
120
Urine flow
(mi/mm)
Csm
(mi/mm)
140 —./\
130
\ Low salt intake\J.P-Chronic
gloiheonephritis12
1
C
2
1
1
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Table 4. Effects of spironolactone and mineralocorticoid administration
V UNa UK CR20 1Na
mi/mm mEq/liter mEq/liter mi/mm mEq/iiter niEq/iiter
Patient
Conta Spironb Cont Spiron Cont Spiron Cont Spiron Cont Spiron Cont Spiron
Spironolactone administration
J. C. 2.05 1.90 12 29 22 18 + 1.09 +0.73 139 136 3.8 4.4
P.N. 1.92 2.22 4 27 24 15 +0.96 +1.16 138 139 4.7 5.3
J. J. 0.81 0.96 7 54 28 12 + 0.22 + 0.04 142 137 4.6 5.2
Conte Mineral' Cont Mineral Cont Mineral Cont Mineral Cont Mineral Cont Mineral
Mineralocorticoid administration
J.C. 1.89 1.51 64 30 27 43 +0.036 +0.083 145 144 4.2 3.7
P. N. 2.05 1.83 65 27 12 40 —0.051 +0.423 137 142 5.1 4.7
J. J. 1.24 1.20 64 49 17 27 +0.158 +0.168 139 142 4.6 4.8
a Cont = Mean values of last 3 days of low sodium intake prior to the diluting and concentrating tests.
b Spiron = Mean values after 3 to 5 days of spironolactone treatment and continued low sodium intake.
c Cont = Mean value of last 3 days of normal sodium intake prior to the diluting and concentrating tests.
ci Mineral = Mean values of first 3 days of mineralocorticoid treatment on normal sodium intake.
Table 5. The effect of sodium intake on solute-free water reabsorption (TcH2O) during a mannitol diuresis
.Time
V
mi/mm
U/Posm Cosm
mi/mm
TCH2O
mi/mm
Patient miii
normal low normal low normal low normal low
J. C. 0 0.83 1.03 1.20 1.07 1.00 1.10 +0.17 +0.07
Polycystic 30 4.60 3.23 1.20 1.02 5.52 3.29 +0.92 +0.06
disease 60
90
6.61 3.80
4.14 3.26
1.15 1.00
1.17 0.96
7.60 3.82
4.84 3.12
+0.99 +0.02
+0.70 —0.14
P. N. 0 1.52 1.53 1.10 0.74 1.67 1.13 +0.15 —0.40
Interstitial 30 2.91 2.63 1.06 0.65 3.08 1.71 +0.17 —0.92
nephritis 60
90
3.66 3.44
3.40 2.08
1.05 0.75
1.07 0.75
3.83 2.59
3.63 1.56
+0.17 —0.85
+0.23 —0.52
J. J. 0 1.25 0.90 0.96 0.94 0.86 1.17 +0.27 —0.04
Interstitial 30 1.80 2.39 0.93 0.90 1.67 2.15 —0.13 —0.24
nephritis 60
90
120
3.78 2.90
3.55 2.80
2.34 2.33
0.85 0.90
0.92 0.87
0.95 0.92
3.19 2.60
3.25 2.42
2.23 2.14
—0.59 —0.30
—0.30 —0.38
—0.13 —0.19
Mean
0 1.20 1.15
±0.2
1.09 0.92
±0.1
1.18 1,13 +0.20 —0.12
SEM 30—120 3.68 2.87 1.04 0.87
±0.04
3.88 2.49 0.20 —0.35
0
30—120
<0.1
<0.05
<0.1
<0.01
<0.1
<0.01
<0.1
<0.01
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was associated with a modest increase in GFR in all
three patients.
Potassium balance was not altered consistently and
the plasma potassium concentration did not differ
during the periods of normal and low sodium intake.
Fecal potassium loss was not affected by the sodium
intake but in some cases rather significant losses were
present on both normal and low sodium intakes. In
one patient (J. P.) with marked renal impairment
(GFR: 3.5 to 5.2ml/min) and severe hyponatremia
during sodium restriction, approximately 50 % of
the daily potassium intake was excreted in the feces.
Effect of prolonged sodium restriction on renal
concentrating and diluting capacity (Figs. 3 to 5,
Table 5). Impairment of renal concentrating ability
was demonstrated in every patient during the period
of normal sodium intake (Fig. 3). In five patients
(J.P., J.J., N.D., W.M., and P.N.) the maximal
urinary osmolality remained below that of plasma
0
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0
300
after fluid deprivation and vasopressin administration,
i.e., so-called vasopressin-resistant hyposthenuria [11].
Prolonged sodium deprivation and decreased solute
excretion was not associated with improved concen-
trating ability in any of the nine patients. In fact, in
nine of the eleven studies the maximal urinary osmo-
lality was lower during the period of low sodium
intake. The maximal urinary osmolality averaged
350± 39 mOsm/kg on a normal sodium diet, and
281 mOsm/kg on a low sodium diet (P<0.05).
The largest decrease in urinary osmolality was ob-
served in the patient with a unilateral kidney and the
least impairment of glomerular filtration rate (L. H.).
Maximal TH2O formation was examined during
mannitol diuresis in three patients on both a normal
and low sodium intake (Table 5). On a low sodium
intake, hypotonic urine was excreted by all three
patients, i.e., TCH2O formation became negative.
TCH2O formation became negative in only one patient
(J.J.) during mannitol diuresis on a normal sodium
intake. The addition of mineralocorticoid to the
normal sodium intake did not affect either maximal
urinary osmolality or TCH2O formation.
The effect of sodium intake on diluting ability is
shown in Fig. 4. The minimal urinary osmolality on
Sodium intake
Fig. 4. Effect of prolonged sodium restriction to improve diluting
capacity. The minimal urinary osmolality achieved during an
acute water load was lower in each study during low sodium as
compared to normal sodium intake.
Sodium intakeNormal
Normal Low
Fig. 3. Effect of prolonged sodium restriction on maximal urinary
osmolality. Maximal urinary osmolality diminished in 9 of
II patients during sodium restriction.
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a normal sodium intake was high in all nine patieuts
(range: 80 to 230 mOsm/kg), but it was significantly
lower during sodium restriction. The minimal osmo-
lality averaged 180 9 mOsm/kg on the normal sodium
intake and 124± 1 mOsm/kg on a low sodium intake
(P<0.00l). In three patients the administration of
mineralocorticoid during a normal sodium intake
was associated with a diminution in minimal urinary
osmolality, and the administration of spironolactone
during low sodium intake was associated with an
increase in minimal urinary osmolality (Fig. 5).
Discussion
The present results suggest that alterations in
aldosterone activity may be of physiological impor-
tance in the renal response to sodium restriction in
patients with chronic renal disease. The observed
increase in urinary aldosterone excretion during so-
dium restriction in these patients is compatible with
such a thesis. Nevertheless, this observation alone was
insufficient to establish a cause and effect relationship
between increased aldosterone excretion and decreased
urinary sodium excretion. For this reason, studies
were undertaken in three patients to assess the effect
of a spironolactone-mediated inhibition of the action
of aldosterone. In each instance urinary sodium
excretion increased substantially during the administra-
tion of spironolactone despite continued dietary
sodium restriction (Table 4). Since spironolactone is
thought to exert its effect on renal tubular sodium
reabsorption via direct inhibition of the action of
aldosterone [12], the present results would seem to
provide strong evidence for an aldosterone-induced
enhancement of sodium reabsorption during sodium
restriction in chronic renal disease. In addition, the
exogenous administration of mineralocorticoids was
found to mimic the urinary effects of sodium restric-
tion even in the presence of a normal sodium intake
(Table 4). Taken together, therefore, the present results
seem to suggest strongly that aldosterone is of physio-
logical importance in the control of sodium meta-
bolism in chronic renal disease. However, one must
acknowledge the possibility that alterations in aldo-
sterone activity may be important in the regulation of
sodium excretion in patients with moderate renal im-
pairment, but that it exerts very little influence in
patients with severe end-stage renal impairment. In
this regard, many of the studies of Slatopolsky et al [6]
which indicated that a "third factor" might be in-
volved in the regulation of sodium excretion in chronic
renal failure were performed in patients with severe
renal impairment. In the present study the glomerular
filtration rates were 54, 24 and 5 mI/mm in the three
patients who received spironolactone during dietary
sodium restriction. In all three patients a large in-
crease in urinary sodium excretion was observed
during the administration of spironolactone and, in
fact, the largest natriuresis was observed in the
patient (J.J.) with the lowest filtration rate. These
present results are therefore compatible with the thesis
that aldosterone is an important regulator of urinary
sodium excretion at all levels of glomerular filtration
rate in patients with chronic renal disease. However,
before this tentative conclusion can be accepted
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Influence of aldosterone in chronic renal disease 165
finally, additional studies of patients with severe renal
impairment will be required. It should also be empha-
sized that the demonstration of a physiological role
of aldosterone in the regulation of sodium excretion
in chronic renal disease in no way precludes an
additional role of other factors, such as changes in
glomerular filtration rate and the activity of "third
factor", instead an interaction between all of these
factors seems most likely.
The possibility that aldosterone might not exert a
significant influence on sodium excretion in chronic
renal disease was based, at least partially, on the
finding that the majority of patients with severe
chronic renal disease may exhibit an increased aldo-
sterone secretory rate [8, 9]. These results, [8, 9] how-
ever, may be related to methodological problems in-
volved in measuring aldosterone secretory rates in
patients with chronic renal disease rather than being
indicative of increased aldosterone production. Cope
and Pearson [8] have reported that, in contrast to
normal subjects, the excretion of the metabolite that
is used to measure aldosterone secretion may be
delayed considerably longer than 24 hours in patients
with chronic renal disease. Since measurements of
aldosterone secretion are based on the excretion of
the majority of the measured metabolite in 24 hours
after the injection of isotope-labeled aldosterone,
measurements in chronic renal disease are difficult to
interpret even when corrections for the delayed ex-
cretion of the metabolite are attempted [8]. Hayslett
et al [13] have used an in vitro assay method of
adrenal glands in azotemic rats to assess aldosterone
production, thereby avoiding any methodological error
related to impaired renal excretion. These investiga-
tors [13] failed to find any evidence of increased aldo-
sterone production in this experimenaI model of
renal failure.
in the present study repeated measurements of
aldosterone excretion in the same patient were used
as a qualitative index of adrenal responsiveness to salt
restriction in patients with chronic renal disease.
Steady-state conditions were insured by maintaining
the patients on the same sodium intake for at least
one to two weeks prior to measuring the 24 hour
excretion rate of aldosterone. During both normal and
low dietary sodium intake three consecutive daily
measurements were obtained. Under such steady-
state conditions and assuming that endogenous
aldosterone metabolism remains unaltered, the ob-
served increase in aldosterone excretion should provide
a reasonable qualitative index of an increase in aldo-
sterone production. The observed decrease in gb-
merular filtration rate during sodium restriction should
tend, if anything, to decrease the measured rate of
aldosterone excretion; thus changes of filtration rate
would not seem to provide an explanation for the
observed increase in aldosterone excretion.
Although it was not our purpose to examine whether
the majority of patients with chronic renal disease are
in a state of "hyperaldosteronism", the demonstra-
tion of a normal adrenal responsiveness to salt restric-
tion in the present patients is most compatible with
the results of Hayslett et al [13] which suggested that
aldosterone production was normal in uremia. In
the present study, aldosterone excretion was found to
be within the range of normal during ingestion of
norm& sodium intake. It should be emphasized, how-
ever, that a normal rate of aldosterone production
could be associated with a normal rate of aldosterone
excretion by diseased kidneys in the presence of an
elevated plasma concentration of aldosterone. Never-
theless, even if the plasma concentration of aldosterone
should be found to be elevated in some patients with
chronic renal disease, the present results would seem
to somewhat mute the physiological significance of
such a finding. In this regard, the most important
question concerning the physiological aspects of aldo-
sterone metabolism in chronic renal disease would
seem to be whether aldosterone still exerts a significant
influence on renal adjustments to alterations in dietary
sodium intake. The present finding that the decrease
in urinary sodium excretion during sodium restriction
may be reversed by spironolactone, and duplicated on
a normal sodium intake by exogenous mineralo-
corticoid administration, supports such a physiological
role of aldosterone in chronic renal disease. The
concept that chronically diseased kidneys remain
responsive to humoral substances which regulate
tubular reabsorption is not without precedent. Slato-
poisky et al [14] have recently shown that the regula-
tion of tubular phosphate reabsorption in chronic
renal disease remains under the control of parat-
hormone activity.
Although increased aldosterone activity, enhanced
distal sodium reabsorption and increased free-water
excretion were consistently observed during sodium
restriction in eight patients, in one patient (J.P.,
Fig. 2) sodium excretion did not diminish significantly
and free-water clearance did not increase during
sodium restriction. In the presence of a constant fluid
intake and urine output this combination of events
was associated with the rapid development of hypo-
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natremia such as that observed in salt-losing nephritis
[15—171. In this same patient sodium restriction on
two occasions was associated with a significant in-
crease in aldosterone excretion. Therefore, in contrast
to the other eight patients, the presence of a physiologi-
cal role for aldosterone could be questioned in this
patient.
The importance of aldosterone in potassium meta-
bolism in chronic renal disease was also examined in
the present study. Urinary potassium excretion and the
plasma potassium concentration were not significantly
different during normal or low sodium intake in the
present patients. In view of the findings of increased
aldosterone activity and diminished sodium excretion
during sodium restriction, a concomitant increase in
potassium excretion might have been expected if the
rate of sodium delivery to the distal nephron remained
unchanged. The constancy of urinary potassium ex-
cretion during sodium restriction thus suggested that a
decreased rate of sodium delivery to the distal tubule
occurred during sodium restriction, and that it ob-
scured the tendency of increased aldosterone activity
to increase potassium secretion.2 The decreased rate
of glomerular filtration provided a probable mecha-
nism whereby the rate of distal sodium delivery may
have been decreased during sodium restriction, but
an additional effect of increased proximal sodium re-
absorption cannot be excluded [181. The effect of
spironolactone to decrease potassium excretion and
increase plasma potassium concentration during so-
dium restriction supported the hypothesis that the
constancy of urinary potassium excretion, in spite
of decreased distal sodium delivery during sodium
restriction, was at least partially related to increased
aldosterone activity. In contrast to the renal effect of
aldosterone, the excessive fecal losses of potassium
in the present patients were not altered during sodium
restriction and increased aldosterone activity. This
finding confirms the earlier work of Hayes et al
[19, 20] who were unable to demonstrate an effect of
either sodium restriction or spironolactone on fecal
potassium losses in patients with chronic renal
disease.
The importance of aldosterone in water metabolism
in chronic renal disease was also investigated in the
2 Although there is now experimental evidence that the tubular
reabsorption of sodium and the tubular secretion of potassium
are not necessarily coupled, altered distal sodium delivery in
the presence of supraphysiological doses of aldosterone is
consistently associated with parallel changes in urinary po-
tassium excretion [4].
present study. Since changes of fluid [21] and protein
intake [22] may influence renal concentrating capacity,
the present patients were maintained on the same
fluid and protein intake throughout the study. Pro-
longed sodium restriction was found to be associated
with a diminution in maximal urinary osmolality and
solute-free water reabsorption. Although it has been
demonstrated that sodium restriction of three days
duration does not affect maximal urinary osmolality
in patients with impaired renal function [23], sodium
restriction in normal man [24] and dog [25] has been
shown to decrease solute-free water reabsorption. The
present observations provide the first demonstration
of an effect of sodium restriction on the renal concen-
trating mechanism in chronic renal disease. This
defect in renal concentrating capacity during sodium
restriction did not seem to be related to increased
aldosterone activity since it could not be produced
by the administration of exogenous mineralocorticoid
in the presence of normal sodium intake. Although
Giebisch and Lozano [26] found that the chronic
administration of aldosterone was associated with a
diminution in solute-free water reabsorption in dogs,
the diminished plasma potassium concentration which
was observed in their experiments could have been
responsible for the renal concentrating defect [27]. In
the present patients, prolonged sodium restriction was
associated with a diminution in solute-free water
reabsorption in the absence of any change in the
plasma potassium concentration.
A decreased delivery of sodium to the thick ascen-
ding limb of the 1oop of Henle, as a result of the
diminution in filtration rate, is a possible mechanism
for the diminution in renal concentrating capacity
during sodium restriction. There is, however, experi-
mental evidence that a decrease in glomerular filtra-
tion rate, of a similar degree as that observed in the
present study, is associated with an increase, not a
decrease, in urinary osmolality in experimental animals
undergoing a water diuresis [28, 29]. In hydropenic
animals, however, a decrease in sodium delivery to the
ascending limb could conceivably decrease rather than
increase urine osmolality. In either case, further
studies are indicated to define the mechanism of the
diminution in renal concentrating capacity that is
associated with sodium restriction in chronic renal
disease. The present results, however, suggest that this
effect is not a result of increased aldosterone activity
during sodium restriction.
In contrast to the defect in renal concentrating
capacity, an improved diluting capacity was observed
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during sodium restriction. The improved diluting
capacity could be reversed by the administration of
spironolactone despite continued sodium restriction,
and it could be duplicated by the administration of
exogenous mineralocorticoid and a normal sodium
intake. These findings would thus suggest that aldo-
sterone is important in the improved diluting ability
during sodium restriction in chronic renal disease.
The results however should not be considered to ex-
clude an additional role of diminished solute load per
nephron [23].
In summary, the results of the present study suggest
that aldosterone is of physiological importance in
sodium, potassium and water metabolism in patients
with chronic renal disease. The diminution in sodium
excretion observed in these patients during sodium
restriction was associated with an increase in aldo-
sterone activity, as judged by a qualitively normal in-
crease in aldosterone excretion. This decrease in
sodium excretion could be reversed by the administra-
tion of spironolactone during continued sodium re-
striction, and duplicated by the administration of
exogenous mineralocorticoid despite a normal sodium
intake. Urinary potassium excretion was unaltered
during sodium restriction, although the concomitant
decrease in glomerular filtration rate suggested a
decreased distal delivery of sodium. The kaliuresis and
increased plasma potassium concentration during
spironolactone administration and sodium restriction
suggested that increased aldosterone activity may have
allowed a constancy of urinary potassium excretion
despite the diminished distal delivery of sodium.
Sodium restriction was associated with a diminished
maximal urinary osmolality and maximal solute-free
water reabsorption which could not be duplicated by
exogenous mineralocorticoid administration and a
normal sodium intake. However, the improved renal
diluting capacity during sodium restriction could be
reproduced by the exogenous administration of
mineralocorticoid and reversed by spironolactone.
Reprint requests to Dr. Robert W. Schrier, Department of
Medicine, Cardiovascular Research Institute, University of
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